Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Ocular Therapeutix Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Ocular Therapeutix Inc (OCUL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 14,294,420 | $104,778,099 | +12% | 3.39% |
| 2. | VenBio Select Advisor Kurt Von Emster | 8,060,000 | $59,079,800 | 0.92% | |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 5,200,000 | $38,116,000 | +45% | 0.07% |
| 4. | Citadel Investment Group Ken Griffin | 4,811,108 | $35,265,421 | +8% | 0.01% |
| 5. | Octagon Capital Advisors Ting Jia | 2,425,000 | $17,775,250 | 3.44% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.96 | 10,000 | $69,600.00 | 172,704 | 2025-05-08 | Filing | |
| $7.52 | 930,851 | $6,999,999.52 | 8,591,401 | 2024-02-26 | Filing | |
| $3.25 | 1,538,461 | $4,999,998.25 | 7,660,550 | 2023-12-14 | Filing | |
| $3.81 | 6,500 | $24,765.00 | 6,500 | 2023-08-30 | Filing | |
| $3.50 | 7,328 | $25,648.00 | 6,122,089 | 2022-11-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.05 | 13,861 | $111,581.05 | 206,805 | 2025-06-02 | Filing | |
| $7.17 | 1,862 | $13,350.54 | 281,623 | 2025-05-23 | Filing | |
| $7.17 | 2,974 | $21,323.58 | 207,104 | 2025-05-23 | Filing | |
| $7.18 | 3,024 | $21,712.32 | 262,974 | 2025-05-23 | Filing | |
| $7.18 | 21,219 | $152,352.42 | 3,499,099 | 2025-05-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,878,018 | $101,725,872 | 98.23% | |
| 2. | 12,762,462 | $93,548,846 | 7.96% | |
| 3. | 12,012,397 | $88,050,870 | 0% | |
| 4. | 8,364,515 | $61,311,895 | 0% | |
| 5. | 5,319,148 | $38,989,355 | 5.32% |
News See All
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Ocular Therapeutix Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Ocular Therapeutix second-quarter 2024 earnings conference call. [Operator Instructions].
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2023 Earnings Call Transcript
Operator: Good day. Thank you for standing by. Welcome to the Third Quarter 2023 Ocular Therapeutix Earnings Conference Call. At this time, all participants are in a listen-only mode.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Quarter 2023 Ocular Therapeutics Earnings Conference Call. At this time, all participants are in a listen-only mode.
10 Best Rising Penny Stocks to Buy
Amid too much volatility everyone seems to avoid small companies that are working on disruptive products or services which are yet to show their true effects or results.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Ocular Therapeutics First Quarter 2023 Earnings Conference Call. . Please be advised that today's conference is being recorded.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Thank you for standing by and welcome to the Ocular Therapeutix Fourth Quarter and Year-End 2022 Earnings Conference Call.
Hedge Funds Are Crazy About Ocular Therapeutix Inc (OCUL)
With the second-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the third ...
Hedge Funds Have Never Been This Bullish On Ocular Therapeutix Inc (OCUL)
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.